ClinicalTrials.gg
CompletedNCT00689338ICEUpdated May 30, 2011Results posted

Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study

A Phase 3 interventional study of Anidulafungin and Fluconazole in Invasive Candidiasis, sponsored by Pfizer. Completed at 61 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-30.

Primary conditionCandidemiaRegistry: Candidiasis, InvasiveReclassifiedWhy we changed it
Registry
Candidiasis, Invasive — the first condition term the registry derived for this study.
ClinicalTrials.gg
Candidemia
Why
  1. The study's title name Candidemia, a narrower term within Candidiasis, Invasive.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
216
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing anidulafungin in Candidemia — none open to participants now, none under way, none of them phase 3. Anidulafungin · Candidemia.

Enrollment
3rd of 11
216 · median 70
Started
2008
with 4 others
Phase 3
5 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
9 of 11
Pfizer

Among the 11 studies testing anidulafungin in Candidemia, this one is the 3rd largest by enrollment, is one of 5 that started in 2008, is one of 5 in phase 3, and was the 7th registered.

Candidemia

73 studies on the registry are indexed under Candidemia; 5 are open to participants now.

Browse Candidemia studies →

Open to participants now

None of the 11 studies testing anidulafungin in Candidemia is open now. The open studies under Candidemia, anywhere →

About anidulafungin

Anidulafungin: first FDA approval 2006 (ERAXIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2 Candidemia studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing anidulafungin in Candidemia as a file.
02

Study summary

To evaluate the efficacy and safety of anidulafungin in the treatment of systemic fungal infections in intensive care and critical care unit patients.

03

Conditions studied

  • Invasive Candidiasis

Browse trials for

Keywords

  • Candida
  • Candidemia
  • Systemic Candidiasis
  • ICU
  • Intensive Care Unit
  • Critical Care Unit
  • Anidulafungin
  • Ecalta
  • Eraxis
  • Fluconazole
  • Voriconazole
04

In context

Candidemia Reclassified

73 studies on the registry are indexed under Candidemia; 5 are open to participants now.

This study's enrollment of 216 is above the median of 63 across 44 interventional studies indexed under Candidemia.

Browse Candidemia studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Candidemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Candidiasis, Invasive. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

ICU patients with a diagnosis of documented candidemia or invasive candidiasis and belonging to one or more of the following specific populations:

  • Post-abdominal surgery.
  • Elderly > 65 years old.
  • Renal insufficiency / failure / hemodialysis.
  • Solid tumor.
  • Solid-organ (liver, kidney, lung, heart) transplant recipients.
  • Hepatic insufficiency.
  • Neutropenic including hematology oncology patients.

Exclusion criteria

Exclusion Criteria:

Patients with poor venous access that would preclude IV drug delivery or multiple blood draws.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    Treatment Group

    Option to treat with oral azole therapy following treatment with anidulafungin

    Drug: Anidulafungin · Drug: Fluconazole · Drug: Voriconazole

Interventions

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With Global Treatment Response Success at End of Treatment

    Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).

    Time frame: End of Treatment (Day 14 to Day 56)

Secondary outcomes

  1. Percentage of Participants With Global Response Success at End of Intravenous Treatment (EOIVT)

    Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).

    Time frame: EOIVT (Day 10 up to Day 42)

  2. Percentage of Participants With Global Response Success at 2 Weeks After End of Treatment

    Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).

    Time frame: 2 weeks after End of Treatment (Day 14 + 14 up to Day 56 + 14)

  3. Percentage of Participants With Global Response Success 6 Weeks After End of Treatment

    Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).

    Time frame: 6 weeks after End of Treatment (Day 14 + 42 up to Day 56 + 42)

  4. Time to First Negative Blood Culture

    Negative blood culture defined as first negative culture that was not followed by a positive culture within the next 3 days (or 4 days if negative culture was observed on or after Day 10) from start of study medication until end of intravenous treatment (EOIVT). Time to first negative culture includes the first day of study medication.

    Time frame: Day 1 up to Day 42

  5. Day 90 Survival

    Percentage of participants known or assumed to be alive on Day 90.

    Time frame: Day 90

  6. Time to Successful Intensive Care Unit (ICU) Discharge

    Time from start of study medication to successful ICU discharge (by end of treatment \[EOT\]), defined as being alive on the day after the EOT visit, not being in the ICU on the day after the EOT visit, and being classed as a global treatment success at EOT.

    Time frame: Day 1 up to Day 56

08

Results

Posted May 17, 2011
Limitations and caveats
In a change to the protocol, time to first negative blood/tissue culture will only concern time to first negative blood culture. Lack of regular tissue sampling meant that analysis of time to first tissue culture could not be meaningfully performed.

Participant flow

Adult specific participants were recruited from intensive care unit (ICU) populations.

Participant flow — Overall Study
MilestoneAnidulafungin
Started216
Completed73
Not completed143
Withdrew: Death65
Withdrew: Adverse event13
Withdrew: Insufficient clinical response1
Withdrew: Lack of efficacy6
Withdrew: Other8
Withdrew: Did not meet entrance criteria27
Withdrew: Lost to follow-up5
Withdrew: Withdrawal by subject3
Withdrew: Protocol violation15

Outcome measures

PrimaryPercentage of Participants With Global Treatment Response Success at End of Treatment

Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).

Time frame:
End of Treatment (Day 14 to Day 56)
Reported as:
Number · percentage of participants
Percentage of Participants With Global Treatment Response Success at End of Treatment
percentage of participantsAnidulafungin
Percentage of Participants With Global Treatment Response Success at End of Treatment69.5 (61.6 to 76.6)
SecondaryPercentage of Participants With Global Response Success at End of Intravenous Treatment (EOIVT)

Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).

Time frame:
EOIVT (Day 10 up to Day 42)
Reported as:
Number · percentage of participants
Percentage of Participants With Global Response Success at End of Intravenous Treatment (EOIVT)
percentage of participantsAnidulafungin
Percentage of Participants With Global Response Success at End of Intravenous Treatment (EOIVT)70.7 (62.9 to 77.7)
SecondaryPercentage of Participants With Global Response Success at 2 Weeks After End of Treatment

Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).

Time frame:
2 weeks after End of Treatment (Day 14 + 14 up to Day 56 + 14)
Reported as:
Number · percentage of participants
Percentage of Participants With Global Response Success at 2 Weeks After End of Treatment
percentage of participantsAnidulafungin
Percentage of Participants With Global Response Success at 2 Weeks After End of Treatment60.2 (51.1 to 68.7)
SecondaryPercentage of Participants With Global Response Success 6 Weeks After End of Treatment

Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).

Time frame:
6 weeks after End of Treatment (Day 14 + 42 up to Day 56 + 42)
Reported as:
Number · percentage of participants
Percentage of Participants With Global Response Success 6 Weeks After End of Treatment
percentage of participantsAnidulafungin
Percentage of Participants With Global Response Success 6 Weeks After End of Treatment50.5 (40.7 to 60.2)
SecondaryTime to First Negative Blood Culture

Negative blood culture defined as first negative culture that was not followed by a positive culture within the next 3 days (or 4 days if negative culture was observed on or after Day 10) from start of study medication until end of intravenous treatment (EOIVT). Time to first negative culture includes the first day of study medication.

Time frame:
Day 1 up to Day 42
Reported as:
Mean · days
Time to First Negative Blood Culture
daysAnidulafungin
Time to First Negative Blood Culture3.7 (3.0 to 4.3)
SecondaryDay 90 Survival

Percentage of participants known or assumed to be alive on Day 90.

Time frame:
Day 90
Reported as:
Number · percentage of participants
Day 90 Survival
percentage of participantsAnidulafungin
Day 90 Survival54.1 (46.3 to 61.8)
Statistical analysis
  • Anidulafungin · Kaplan-Meier · Estimate of survival: 53.8 · 95% CI 45.9 to 60.9
SecondaryTime to Successful Intensive Care Unit (ICU) Discharge

Time from start of study medication to successful ICU discharge (by end of treatment \[EOT\]), defined as being alive on the day after the EOT visit, not being in the ICU on the day after the EOT visit, and being classed as a global treatment success at EOT.

Time frame:
Day 1 up to Day 56
Reported as:
Mean · days
Time to Successful Intensive Care Unit (ICU) Discharge
daysAnidulafungin
Time to Successful Intensive Care Unit (ICU) Discharge16.2 (13.3 to 19.1)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Anidulafungin—107/216 (49.5%)78/216 (36.1%)
Most frequent serious events
Showing 10 of 91
Most frequent serious events
EventAnidulafungin
Septic shockInfections and infestations21/216
Multi-organ failureGeneral disorders12/216
Cardiac arrestCardiac disorders10/216
Respiratory failureRespiratory, thoracic and mediastinal disorders9/216
SepsisInfections and infestations6/216
Renal failureRenal and urinary disorders6/216
Cardiac failureCardiac disorders5/216
Cardio-respiratory arrestCardiac disorders5/216
Abdominal operationSurgical and medical procedures5/216
PneumoniaInfections and infestations3/216
Most frequent other events
Most frequent other events
EventAnidulafungin
DiarrhoeaGastrointestinal disorders20/216
AnaemiaBlood and lymphatic system disorders16/216
HypertensionVascular disorders16/216
HypotensionVascular disorders15/216
NauseaGastrointestinal disorders12/216
PyrexiaGeneral disorders12/216
ThrombocytopeniaBlood and lymphatic system disorders11/216
Atrial fibrillationCardiac disorders11/216
TachycardiaCardiac disorders11/216

Baseline characteristics

Age, Customized
Age, Customized(participants)Anidulafungin
<18 years0
18 to 44 years27
45 to 64 years89
≥ 65 years100
Sex: Female, Male
Sex: Female, Male(Participants)Anidulafungin
Female85
Male131
09

Study locations

61 sites
  • Pfizer Investigational Site
    Wien, A-1090, Austria
  • Pfizer Investigational Site
    Brussels, B-1070, Belgium
  • Pfizer Investigational Site
    Brussel, 1090, Belgium
  • Pfizer Investigational Site
    Gent, 9000, Belgium
  • Pfizer Investigational Site
    Leuven, 3000, Belgium
  • Pfizer Investigational Site
    Liege, B-4000, Belgium
  • Pfizer Investigational Site
    Yvoir, 5530, Belgium
  • Pfizer Investigational Site
    Hamilton, Ontario L8N 3Z5, Canada
  • Pfizer Investigational Site
    Hamilton, Ontario L8N 4A6, Canada
  • Pfizer Investigational Site
    Quebec, G1R 2J6, Canada
  • Pfizer Investigational Site
    Brno, 656 91, Czech Republic
  • Pfizer Investigational Site
    Ostrava, 708 52, Czech Republic
  • Pfizer Investigational Site
    Praha 10, 100 34, Czech Republic
  • Pfizer Investigational Site
    Koebenhavn OE, 2100, Denmark
  • Pfizer Investigational Site
    Odense C, 5000, Denmark
  • Pfizer Investigational Site
    Amiens, 80054, France
  • Pfizer Investigational Site
    Bordeaux, 33076, France
  • Pfizer Investigational Site
    Clichy, 92110, France
  • Pfizer Investigational Site
    Lyon, 69433, France
  • Pfizer Investigational Site
    Marseille, 13385, France
  • Pfizer Investigational Site
    Montpellier, 34295, France
  • Pfizer Investigational Site
    Paris Cedex 18, 75877, France
  • Pfizer Investigational Site
    Villejuif Cedex, 94804, France
  • Pfizer Investigational Site
    Berlin, 10117, Germany
  • Pfizer Investigational Site
    Freiburg, 79106, Germany
  • Pfizer Investigational Site
    Wuppertal, 42283, Germany
  • Pfizer Investigational Site
    Kifisia, Athens 14561, Greece
  • Pfizer Investigational Site
    Haidari, Attiki 12462, Greece
  • Pfizer Investigational Site
    Budapest, 1106, Hungary
  • Pfizer Investigational Site
    Budapest, 1125, Hungary
  • Pfizer Investigational Site
    Pisa, 56124, Italy
  • Pfizer Investigational Site
    Roma, 00161, Italy
  • Pfizer Investigational Site
    Roma, 00168, Italy
  • Pfizer Investigational Site
    Torino, 10143, Italy
  • Pfizer Investigational Site
    Udine, 33100, Italy
  • Pfizer Investigational Site
    Ede, 6716 RP, Netherlands
  • Pfizer Investigational Site
    Rotterdam, 3083 AN, Netherlands
  • Pfizer Investigational Site
    Krakow, 31-501, Poland
  • Pfizer Investigational Site
    Lodz, 90-153, Poland
  • Pfizer Investigational Site
    Coimbra, 3040-853, Portugal
  • Pfizer Investigational Site
    Lisboa, 1349-019, Portugal
  • Pfizer Investigational Site
    Porto, 4200-072, Portugal
  • Pfizer Investigational Site
    Porto, 4200-319, Portugal
  • Pfizer Investigational Site
    Bucuresti, 022328, Romania
  • Pfizer Investigational Site
    Iasi, 700111, Romania
  • Pfizer Investigational Site
    Moscow, 115478, Russian Federation
  • Pfizer Investigational Site
    Moscow, 121552, Russian Federation
  • Pfizer Investigational Site
    Moscow, 125167, Russian Federation
  • Pfizer Investigational Site
    Saint-Petersburg, 191015, Russian Federation
  • Pfizer Investigational Site
    Saint-Petersburg, 194291, Russian Federation
  • Pfizer Investigational Site
    Bratislava, 033 10, Slovakia
  • Pfizer Investigational Site
    Bratislava, 851 07, Slovakia
  • Pfizer Investigational Site
    Kosice, 041 66, Slovakia
  • Pfizer Investigational Site
    Gorukle, Bursa 16045, Turkey
  • Pfizer Investigational Site
    Ankara, 06100, Turkey
  • Pfizer Investigational Site
    Trabzon, 61080, Turkey
  • Pfizer Investigational Site
    Dnipropetrovsk, 49600, Ukraine
  • Pfizer Investigational Site
    Donetsk, 84003, Ukraine
  • Pfizer Investigational Site
    Leeds, West Yorkshire LS1 3EX, United Kingdom
  • Pfizer Investigational Site
    Liverpool, L7 8XP, United Kingdom
  • Pfizer Investigational Site
    London, SE5 9RS, United Kingdom
10

References and documents

Publications

  • De Rosa FG, Busca A, Capparella MR, Yan JL, Aram JA. Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clin Drug Investig. 2021 Jun;41(6):539-548. doi: 10.1007/s40261-021-01024-7. Epub 2021 Apr 23. PubMed 33891293 ↗
  • Sganga G, Wang M, Capparella MR, Tawadrous M, Yan JL, Aram JA, Montravers P. Evaluation of anidulafungin in the treatment of intra-abdominal candidiasis: a pooled analysis of patient-level data from 5 prospective studies. Eur J Clin Microbiol Infect Dis. 2019 Oct;38(10):1849-1856. doi: 10.1007/s10096-019-03617-9. Epub 2019 Jul 6. PubMed 31280481 ↗
  • Kontoyiannis DP, Bassetti M, Nucci M, Capparella MR, Yan JL, Aram J, Hogan PA. Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses. 2017 Oct;60(10):663-667. doi: 10.1111/myc.12641. Epub 2017 Jun 9. PubMed 28597967 ↗
  • Kullberg BJ, Vasquez J, Mootsikapun P, Nucci M, Paiva JA, Garbino J, Yan JL, Aram J, Capparella MR, Conte U, Schlamm H, Swanson R, Herbrecht R. Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials. J Antimicrob Chemother. 2017 Aug 1;72(8):2368-2377. doi: 10.1093/jac/dkx116. PubMed 28459966 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2008
First posted
Jun 3, 2008
Start
Jul 2008
Primary completionActual
May 2010
CompletionActual
May 2010
Results first posted
May 17, 2011
Last update
May 30, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00689338
Lead sponsor
Pfizer
First posted
Jun 3, 2008
Start date
Jul 2008
Primary completion
May 2010
Completion
May 2010
Results posted
May 17, 2011
Last update
May 30, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anidulafungin · Fluconazole · Voriconazole

Start the discussion